US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
ES2645698T3
(es)
|
2001-11-30 |
2017-12-07 |
Amgen Fremont Inc. |
Animales transgénicos que portan genes de cadena ligera de Ig humana
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
AU2003205173C1
(en)
*
|
2002-01-18 |
2009-01-29 |
Eisai, Inc. |
A method for generating engineered cells for locus specific gene regulation and analysis
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
ES2442615T5
(es)
|
2002-07-18 |
2023-03-16 |
Merus Nv |
Producción recombinante de mezclas de anticuerpos
|
CA2496233A1
(en)
*
|
2002-09-09 |
2004-03-18 |
California Institute Of Technology |
Methods and compositions for the generation of humanized mice
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
GB2408980B
(en)
*
|
2003-12-09 |
2006-06-07 |
Nat Biolog Standards Board |
Genetic reference materials
|
LT2311874T
(lt)
|
2004-07-22 |
2017-11-27 |
Erasmus University Medical Center Rotterdam |
Rišančiosios molekulės
|
CA2638774C
(en)
*
|
2006-03-31 |
2015-11-24 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
BRPI0712224B8
(pt)
|
2006-06-02 |
2021-05-25 |
Regeneron Pharma |
anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
|
WO2007147167A2
(en)
*
|
2006-06-16 |
2007-12-21 |
Porous Power Technologies, Llc |
Optimized microporous structure of electrochemical cells
|
ES2466669T3
(es)
|
2006-10-02 |
2014-06-10 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos humanos con alta afinidad para el receptor IL-4 humano
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
MX2009010120A
(es)
|
2007-03-22 |
2009-10-19 |
Ucb Pharma Sa |
Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
|
PT2336329E
(pt)
*
|
2007-06-01 |
2012-12-24 |
Omt Inc |
Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
|
ES2517872T3
(es)
|
2007-08-10 |
2014-11-04 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos humanos de alta afinidad para el factor de crecimiento nervioso humano
|
US9693539B2
(en)
*
|
2007-08-10 |
2017-07-04 |
E. R. Squibb & Sons, L.L.C. |
HCO32 and HCO27 and related examples
|
GB0718029D0
(en)
*
|
2007-09-14 |
2007-10-24 |
Iti Scotland Ltd |
Two step cluster deletion and humanisation
|
KR101680906B1
(ko)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
AU2008335178A1
(en)
|
2007-12-10 |
2009-06-18 |
Ablexis Llc |
Methods for sequential replacement of targeted region by homologous recombination
|
US20090208832A1
(en)
*
|
2008-02-17 |
2009-08-20 |
Porous Power Technologies, Llc |
Lamination Configurations for Battery Applications Using PVDF Highly Porous Film
|
US20090223155A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Building Construction Applications for Porous Material
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
US20090226683A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Porous Material Uses in Furniture
|
US20090227163A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Protective Apparel with Porous Material Layer
|
US20090222995A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Bedding Applications for Porous Material
|
US20110123530A1
(en)
*
|
2008-03-31 |
2011-05-26 |
Arron Joseph R |
Compositions and methods for treating and diagnosing asthma
|
DK2288623T3
(da)
*
|
2008-05-23 |
2014-01-27 |
Ablexis Llc |
Fremgangsmåde til frembringelse af enkelt-vl-domæne-antistoffer hos transgene dyr
|
US20100122358A1
(en)
*
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
AU2014203150C1
(en)
*
|
2008-06-27 |
2018-10-18 |
Merus N.V. |
Antibody producing non-human mammals
|
SG10201914027VA
(en)
*
|
2008-06-27 |
2020-03-30 |
Merus Nv |
Antibody producing non-human mammals
|
EP2346994B1
(en)
*
|
2008-09-30 |
2022-02-16 |
Ablexis, LLC |
Knock-in mice for the production of chimeric antibodies
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
CN102292445A
(zh)
|
2008-12-18 |
2011-12-21 |
伊拉兹马斯大学鹿特丹医学中心 |
表达人源化抗体的非人转基因动物及其用途
|
US20100178567A1
(en)
*
|
2008-12-24 |
2010-07-15 |
Porous Power Technologies, Llc |
Mat Forming Spacers in Microporous Membrane Matrix
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
TWI504409B
(zh)
|
2009-03-25 |
2015-10-21 |
Genentech Inc |
新穎抗-α5β1抗體及其用途
|
US9276246B2
(en)
*
|
2009-05-20 |
2016-03-01 |
Samsung Electronics Co., Ltd. |
Treatment and adhesive for microporous membranes
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以dll4拮抗劑與化學治療劑治療癌症之方法
|
KR101962476B1
(ko)
|
2009-07-03 |
2019-03-26 |
아비펩 피티와이 리미티트 |
면역성 접합체 및 그 제조방법
|
US9445581B2
(en)
*
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
DK3241435T3
(da)
*
|
2009-07-08 |
2021-08-23 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
ES2591107T3
(es)
|
2009-10-06 |
2016-11-24 |
Regeneron Pharmaceuticals, Inc. |
Ratones modificados genéticamente e injerto
|
SI2954779T1
(sl)
*
|
2009-12-10 |
2019-06-28 |
Regeneron Pharmaceuticals, Inc. |
Miši, ki proizvajajo težkoverižna protitelesa
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
SG181690A1
(en)
|
2009-12-21 |
2012-07-30 |
Regeneron Pharma |
Humanized fcy r mice
|
US9315581B2
(en)
|
2009-12-23 |
2016-04-19 |
A Vipep Pty Limited |
Immuno-conjugates and methods for producing them
|
US20130045492A1
(en)
*
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
KR102432611B1
(ko)
*
|
2010-02-08 |
2022-08-16 |
리제너론 파마슈티칼스 인코포레이티드 |
일반적인 경쇄 마우스
|
US20130185821A1
(en)
*
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
CA2784211C
(en)
|
2010-02-18 |
2019-12-24 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
TW201138823A
(en)
|
2010-03-24 |
2011-11-16 |
Genentech Inc |
Anti-LRP6 antibodies
|
KR102004106B1
(ko)
|
2010-03-31 |
2019-07-25 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
US8980253B2
(en)
|
2010-04-26 |
2015-03-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
US8961960B2
(en)
|
2010-04-27 |
2015-02-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
AU2011248489B2
(en)
|
2010-04-28 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
|
JP6008838B2
(ja)
|
2010-04-29 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
アスパラギニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
EP2563383B1
(en)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
JP5976638B2
(ja)
|
2010-05-03 |
2016-08-23 |
エータイアー ファーマ, インコーポレイテッド |
アルギニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CA2797978C
(en)
|
2010-05-03 |
2019-12-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
CN103096912A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
WO2011140267A2
(en)
|
2010-05-04 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
|
US8945541B2
(en)
|
2010-05-14 |
2015-02-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
CN103096913B
(zh)
|
2010-05-27 |
2017-07-18 |
Atyr 医药公司 |
与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
SG185703A1
(en)
|
2010-06-11 |
2013-01-30 |
Regeneron Pharma |
Production of fertile xy female animals from xy es cells
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
CN105695415A
(zh)
|
2010-06-17 |
2016-06-22 |
科马布有限公司 |
动物模型及治疗分子
|
CA2794731C
(en)
|
2010-06-18 |
2019-03-19 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
JP6009441B2
(ja)
|
2010-06-22 |
2016-10-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ハイブリッド軽鎖マウス
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
DK2597945T3
(da)
*
|
2010-07-26 |
2020-09-21 |
Trianni Inc |
Transgene dyr og fremgangsmåder til anvendelse deraf
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
ES2612459T3
(es)
*
|
2010-08-02 |
2017-05-17 |
Regeneron Pharmaceuticals, Inc. |
Ratones que producen proteínas de unión que comprenden dominios VL
|
BR112013002535A2
(pt)
|
2010-08-03 |
2019-09-24 |
Hoffmann La Roche |
biomarcadores de leucemia linfocítica crônica (cll)
|
EP2600898A1
(en)
|
2010-08-05 |
2013-06-12 |
F.Hoffmann-La Roche Ag |
Anti-mhc antibody anti-viral cytokine fusion protein
|
MX358859B
(es)
|
2010-08-13 |
2018-09-05 |
Roche Glycart Ag |
Anticuerpos anti-fap y métodos de utilización.
|
CA2808185A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1.beta. and il-18, for treatment of disease
|
JP5841149B2
(ja)
|
2010-08-13 |
2016-01-13 |
ロシュ グリクアート アーゲー |
抗テネイシンca2抗体及び使用の方法
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
JP2013537966A
(ja)
|
2010-08-31 |
2013-10-07 |
ジェネンテック, インコーポレイテッド |
バイオマーカー及び治療の方法
|
EP2635674A4
(en)
|
2010-11-05 |
2014-11-05 |
Transbio Ltd |
MARKERS FOR ENDOTHELIAL STORAGE CELLS AND USES THEREOF
|
JP6163429B2
(ja)
|
2010-11-10 |
2017-07-12 |
ジェネンテック, インコーポレイテッド |
神経疾患免疫治療のための方法及び組成物
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
KR101923282B1
(ko)
|
2010-12-16 |
2018-11-28 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
NZ610976A
(en)
|
2010-12-20 |
2015-07-31 |
Genentech Inc |
Anti-mesothelin antibodies and immunoconjugates
|
WO2012088313A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
RU2013135175A
(ru)
|
2011-01-03 |
2015-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
|
US9217040B2
(en)
|
2011-01-14 |
2015-12-22 |
The Regents Of The University Of California |
Therapeutic antibodies against ROR-1 protein and methods for use of same
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
US9561155B2
(en)
|
2011-01-28 |
2017-02-07 |
Sanofi Biotechnology |
Method of reducing cholesterol levels using a human anti-PCSK9 antibody
|
CA2826566C
(en)
|
2011-02-08 |
2022-09-13 |
Medimmune, Llc |
Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
|
MY162984A
(en)
|
2011-02-15 |
2017-07-31 |
Regeneron Pharma |
Humanized m-csf mice
|
DK2550363T3
(en)
|
2011-02-25 |
2015-03-23 |
Regeneron Pharma |
ADAM6 mice
|
WO2012122590A1
(en)
|
2011-03-14 |
2012-09-20 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
CN105949313B
(zh)
|
2011-03-29 |
2021-06-15 |
罗切格利卡特公司 |
抗体Fc变体
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
AU2012245073B2
(en)
|
2011-04-21 |
2016-02-11 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
DK2631654T3
(en)
|
2011-05-12 |
2015-07-20 |
Regeneron Pharma |
Neuropeptidfrigivelsesassay to sodium
|
ES2567276T3
(es)
|
2011-05-12 |
2016-04-21 |
Genentech, Inc. |
Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
|
SG194917A1
(en)
|
2011-05-16 |
2013-12-30 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
KR101822702B1
(ko)
|
2011-06-13 |
2018-01-26 |
씨에스엘 리미티드 |
G-csfr에 대한 항체 및 이의 용도
|
CN103596984B
(zh)
|
2011-06-15 |
2016-04-13 |
霍夫曼-拉罗奇有限公司 |
抗-人epo受体的抗体及使用方法
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
HUE029855T2
(en)
|
2011-07-05 |
2017-04-28 |
Bioasis Technologies Inc |
p97 antibody conjugates
|
CA2841376C
(en)
|
2011-07-05 |
2023-02-28 |
Duke University |
N-terminal deleted gp120 immunogens
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
EP3321281B1
(en)
|
2011-08-05 |
2019-11-27 |
biOasis Technologies Inc |
P97 fragments with transfer activity
|
PT2739740T
(pt)
|
2011-08-05 |
2020-01-09 |
Regeneron Pharma |
Cadeia leve universal humanizada de murganhos
|
KR101999867B1
(ko)
|
2011-08-11 |
2019-07-12 |
아스텔라스세이야쿠 가부시키가이샤 |
신규 항 인간 ngf 항체
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
JP6333174B2
(ja)
|
2011-08-19 |
2018-05-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗tie2抗体およびその使用
|
BR112014004166A2
(pt)
|
2011-08-23 |
2018-05-29 |
Roche Glycart Ag |
anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção
|
CA2844540C
(en)
|
2011-08-23 |
2018-10-16 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
CA2844141A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
MY170089A
(en)
|
2011-09-16 |
2019-07-04 |
Regeneron Pharma |
Methods for reducing lipoproten(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
|
EP2758534B1
(en)
*
|
2011-09-19 |
2020-04-29 |
Kymab Limited |
Animals, repertoires & methods for the production of human antibodies
|
EP2758055A1
(en)
|
2011-09-19 |
2014-07-30 |
F.Hoffmann-La Roche Ag |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
WO2013052095A2
(en)
|
2011-10-03 |
2013-04-11 |
Duke University |
Vaccine
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
JP6532678B2
(ja)
|
2011-10-14 |
2019-06-19 |
ジェネンテック, インコーポレイテッド |
抗HtrA1抗体及び使用方法
|
BR112014008590A2
(pt)
|
2011-10-15 |
2017-10-24 |
Genentech Inc |
métodos de uso de antagonistas de scd1
|
US10246509B2
(en)
*
|
2011-10-17 |
2019-04-02 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
US9265817B2
(en)
|
2011-10-28 |
2016-02-23 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
ES2914374T3
(es)
|
2011-10-28 |
2022-06-10 |
Regeneron Pharma |
Ratones modificados genéticamente que expresan moléculas quiméricas del complejo de histocompatibilidad mayor (MHC) de clase II
|
HUE035652T2
(en)
|
2011-10-28 |
2018-05-28 |
Regeneron Pharma |
Genetically Modified Major Histocompatibility Complex Mice
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
CN107858332A
(zh)
|
2011-10-28 |
2018-03-30 |
瑞泽恩制药公司 |
T细胞受体基因修饰小鼠
|
WO2013063391A2
(en)
|
2011-10-28 |
2013-05-02 |
Trianni, Inc. |
Transgenic animals and methods of use
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
GB2496375A
(en)
*
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
US9253965B2
(en)
*
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
SG10201605675WA
(en)
*
|
2011-12-20 |
2016-09-29 |
Regeneron Pharma |
Humanized light chain mice
|
WO2013092720A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
IN2014CN04615A
(zh)
|
2011-12-22 |
2015-09-18 |
Astellas Pharma Inc |
|
BR112014014239B1
(pt)
|
2011-12-22 |
2021-10-13 |
F. Hoffmann-La Roche Ag |
Método para selecionar uma célula recombinante de mamífero transfectada estável, método para produzir um anticorpo e vetor de expressão
|
EP3816284A1
(en)
|
2011-12-22 |
2021-05-05 |
F. Hoffmann-La Roche AG |
Expression vector for antibody production in eukaryotic cells
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
JP6242813B2
(ja)
|
2012-01-18 |
2017-12-06 |
ジェネンテック, インコーポレイテッド |
抗lrp5抗体及び使用方法
|
SG10201913428QA
(en)
|
2012-02-01 |
2020-03-30 |
Regeneron Pharma |
Humanized rodents that express heavy chains containing vl domains
|
AU2013216753B2
(en)
|
2012-02-11 |
2017-09-21 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
KR102069397B1
(ko)
|
2012-02-15 |
2020-01-22 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 기재 친화성 크로마토그래피
|
IN2014MN01642A
(zh)
|
2012-02-16 |
2015-07-03 |
Atyr Pharma Inc |
|
EP2821416B1
(en)
|
2012-02-28 |
2018-10-03 |
Astellas Pharma Inc. |
Novel anti-human il-23 receptor antibody
|
EP2820044A1
(en)
|
2012-03-02 |
2015-01-07 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to clostridium difficile toxins
|
EP3165086A1
(en)
|
2012-03-06 |
2017-05-10 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
BR112014018964A2
(pt)
|
2012-03-13 |
2020-05-12 |
F. Hoffmann-La Roche Ag |
Anticorpo anti-vegf e uso de um anticorpo anti-vegf
|
LT3348140T
(lt)
|
2012-03-16 |
2021-01-25 |
Regeneron Pharmaceuticals, Inc. |
Histidinu pakeisti lengvosios grandinės antikūnai ir genetiškai modifikuoti graužikai, išvesti jų gamybai
|
PT2825037T
(pt)
|
2012-03-16 |
2019-08-07 |
Regeneron Pharma |
Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
US9301510B2
(en)
|
2012-03-16 |
2016-04-05 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with pH-dependent binding characteristics
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
*
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
EP2831245A1
(en)
*
|
2012-03-28 |
2015-02-04 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
AU2013249985B2
(en)
|
2012-04-20 |
2017-11-23 |
Merus N.V. |
Methods and means for the production of Ig-like molecules
|
CA2869016C
(en)
*
|
2012-04-25 |
2020-05-05 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
JP2015525071A
(ja)
*
|
2012-06-05 |
2015-09-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法
|
SG10201913429WA
(en)
*
|
2012-06-12 |
2020-03-30 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
RU2015101113A
(ru)
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
KR20150030693A
(ko)
|
2012-07-05 |
2015-03-20 |
제넨테크, 인크. |
발현 및 분비 시스템
|
TW201406785A
(zh)
|
2012-07-09 |
2014-02-16 |
Genentech Inc |
抗cd22抗體及免疫結合物
|
SG11201500142RA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
BR112015000437A2
(pt)
|
2012-07-09 |
2017-06-27 |
Genentech Inc |
imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
|
WO2014011521A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti - cd79b antibodies
|
PL3210627T3
(pl)
|
2012-07-12 |
2023-04-17 |
Hangzhou Dac Biotech Co., Ltd |
Koniugaty zawierające cząsteczki wiążące się z komórką i środek cytotoksyczny
|
KR101774121B1
(ko)
|
2012-07-13 |
2017-09-01 |
로슈 글리카트 아게 |
이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
AU2013296557B2
(en)
|
2012-07-31 |
2019-04-18 |
Bioasis Technologies Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
WO2014025813A1
(en)
|
2012-08-07 |
2014-02-13 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
IN2015KN00414A
(zh)
|
2012-08-21 |
2015-07-17 |
Sanofi Sa |
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
DK2888283T3
(en)
|
2012-08-24 |
2018-11-19 |
Univ California |
ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
EP4374919A2
(en)
|
2012-09-07 |
2024-05-29 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
NZ746089A
(en)
|
2012-09-07 |
2020-05-29 |
Institute For Res In Biomedicine Irb |
Genetically modified non-human animals and methods of use thereof
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
JP6329554B2
(ja)
*
|
2012-10-12 |
2018-05-23 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
宿主細胞改変方法
|
EP3939423B1
(en)
|
2012-11-05 |
2024-03-06 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals and methods of use thereof
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
AU2013341361A1
(en)
|
2012-11-06 |
2015-06-04 |
Medimmune, Llc |
Antibodies to S. aureus surface determinants
|
MA38165A1
(fr)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
|
PE20150945A1
(es)
|
2012-11-13 |
2015-06-26 |
Genentech Inc |
Anticuerpos de antihemaglutinina y metodos de uso
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以dll4拮抗劑治療卵巢癌之方法
|
CN105849086B
(zh)
|
2012-11-24 |
2018-07-31 |
杭州多禧生物科技有限公司 |
亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
|
SI3653049T1
(sl)
|
2012-12-14 |
2024-02-29 |
Omniab, Inc. |
Polinukleotidi, ki kodirajo protitelesa glodavcev s človeškimi idiotipi in živali, ki jih vsebujejo
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
US9963501B2
(en)
*
|
2013-02-06 |
2018-05-08 |
Regeneron Pharmaceuticals, Inc. |
B cell lineage based immunogen design with humanized animals
|
CA2898618A1
(en)
|
2013-02-07 |
2014-08-14 |
Csl Limited |
Il-11r binding proteins and uses thereof
|
RU2017114166A
(ru)
*
|
2013-02-20 |
2019-01-29 |
Регенерон Фармасьютикалс, Инк. |
Не являющиеся человеком животные с модифицированными последовательностями тяжелых цепей иммуноглобулинов
|
CN111484999A
(zh)
|
2013-02-20 |
2020-08-04 |
瑞泽恩制药公司 |
人源化的t细胞共受体的小鼠
|
ES2904803T3
(es)
|
2013-02-20 |
2022-04-06 |
Regeneron Pharma |
Modificación genética de ratas
|
CA2900824A1
(en)
*
|
2013-02-22 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
BR112015018418A2
(pt)
|
2013-02-22 |
2017-07-18 |
Hoffmann La Roche |
métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
MX2015011428A
(es)
|
2013-03-06 |
2016-02-03 |
Genentech Inc |
Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
|
ES2948808T3
(es)
*
|
2013-03-11 |
2023-09-19 |
Regeneron Pharma |
Ratones transgénicos que expresan moléculas del complejo mayor de histocompatibilidad (CMH) de clase II quiméricas
|
WO2014160179A1
(en)
|
2013-03-13 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
SI3501272T1
(sl)
|
2013-03-13 |
2023-05-31 |
Regeneron Pharmaceuticals, Inc. |
Miši, ki izražajo omejen repertoar lahke verige imunoglobulina
|
ES2774549T3
(es)
|
2013-03-13 |
2020-07-21 |
Bioasis Technologies Inc |
Fragmentos de P97 y usos de los mismos
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
AU2014241442B2
(en)
|
2013-03-14 |
2018-11-15 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to GREM 1
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
PL2967012T3
(pl)
|
2013-03-14 |
2021-04-19 |
Erasmus University Medical Center Rotterdam |
Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
|
KR102233349B1
(ko)
|
2013-03-15 |
2021-03-31 |
에이씨 이뮨 에스.에이. |
항-타우(tau) 항체 및 사용 방법
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US10160797B2
(en)
|
2013-03-15 |
2018-12-25 |
Sanofi Pasteur Biologics, Llc |
Antibodies against Clostridium difficile toxins and methods of using the same
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
US20140328849A1
(en)
|
2013-03-15 |
2014-11-06 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
MA38496B2
(fr)
|
2013-03-15 |
2021-01-29 |
Regeneron Pharma |
Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques
|
CA2905798C
(en)
|
2013-03-15 |
2023-01-24 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
KR20200136508A
(ko)
|
2013-04-16 |
2020-12-07 |
리제너론 파마슈티칼스 인코포레이티드 |
랫트 게놈의 표적화된 변형
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
PE20151807A1
(es)
|
2013-04-29 |
2015-12-02 |
Hoffmann La Roche |
Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
*
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US20140331339A1
(en)
*
|
2013-05-03 |
2014-11-06 |
Kymab Limited |
Transgenic Non-Human Assay Vertebrates, Assays and Kits
|
MX2015015970A
(es)
|
2013-05-20 |
2016-09-08 |
Genentech Inc |
Anticuerpos receptores de antitransferina y metodos de uso.
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
WO2014197752A1
(en)
|
2013-06-07 |
2014-12-11 |
Regeneron Pharmaceuticals, Inc. |
Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9
|
RS59354B1
(sr)
|
2013-06-21 |
2019-10-31 |
Sanofi Biotechnology |
Postupci lečenja nosne polipoze davanjem il-4r antagonista
|
KR20160060634A
(ko)
|
2013-08-01 |
2016-05-30 |
어젠시스 인코포레이티드 |
Cd37 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
EP3030653A4
(en)
|
2013-08-07 |
2017-07-26 |
Regeneron Pharmaceuticals, Inc. |
Lincrna-deficient non-human animals
|
MX369208B
(es)
|
2013-08-09 |
2019-10-31 |
Astellas Pharma Inc |
Anticuerpo contra el receptor de tslp humana novedoso.
|
EP3564671B1
(en)
|
2013-08-23 |
2021-09-29 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
JP6608823B2
(ja)
|
2013-08-26 |
2019-11-20 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用
|
WO2015031673A2
(en)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
EP3041846B1
(en)
|
2013-09-02 |
2018-11-07 |
Hangzhou Dac Biotech Co., Ltd |
Novel cytotoxic agents for conjugation of drugs to cell binding molecule
|
RU2016109247A
(ru)
|
2013-09-17 |
2017-10-19 |
Дженентек, Инк. |
Способы применения антител к lgr5
|
WO2015042250A1
(en)
|
2013-09-18 |
2015-03-26 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
|
CN105637087A
(zh)
|
2013-09-18 |
2016-06-01 |
科马布有限公司 |
方法、细胞与生物体
|
TW201546284A
(zh)
|
2013-10-01 |
2015-12-16 |
Kymab Ltd |
動物模式及治療分子
|
US20150140002A1
(en)
|
2013-10-11 |
2015-05-21 |
Sanofi |
Use of a pcsk9 inhibitor to treat hyperlipidemia
|
KR20160068855A
(ko)
|
2013-10-11 |
2016-06-15 |
제넨테크, 인크. |
Nsp4 억제제 및 사용 방법
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
MX2016005159A
(es)
|
2013-10-23 |
2016-07-05 |
Genentech Inc |
Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
|
UA119973C2
(uk)
|
2013-11-06 |
2019-09-10 |
Янссен Байотек, Інк. |
Антитіло до ссl17
|
US10428157B2
(en)
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
CA2924268C
(en)
|
2013-11-21 |
2021-05-18 |
F. Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
MX2016007654A
(es)
|
2013-12-11 |
2017-08-15 |
Regeneron Pharma |
Metodos y composiciones para la modificacion dirigida de un genoma.
|
RS58159B1
(sr)
|
2013-12-11 |
2019-03-29 |
Regeneron Pharma |
Postupci i kompozicije za ciljanu modifikaciju genoma
|
KR20160098328A
(ko)
|
2013-12-13 |
2016-08-18 |
제넨테크, 인크. |
항-cd33 항체 및 면역접합체
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
SG11201604979WA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
PE20210648A1
(es)
|
2013-12-17 |
2021-03-26 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
ES2763429T5
(es)
|
2013-12-17 |
2023-06-21 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
KR20160099083A
(ko)
|
2013-12-24 |
2016-08-19 |
아스테라스 세이야쿠 가부시키가이샤 |
신규 항인간 bdca-2 항체
|
KR102278979B1
(ko)
|
2014-01-03 |
2021-07-19 |
에프. 호프만-라 로슈 아게 |
공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CA2933384A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
BR112016014945A2
(pt)
|
2014-01-03 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
conjugado, formulação farmacêutica e uso
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
CA2935393A1
(en)
|
2014-01-24 |
2015-07-30 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
WO2015116852A1
(en)
|
2014-01-29 |
2015-08-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating rheumatoid arthritis by administering an il-6r antibody
|
BR112016017933A2
(pt)
|
2014-02-03 |
2017-10-10 |
Bioasis Technologies Inc |
?proteínas de fusão p97?
|
KR20160111039A
(ko)
|
2014-02-08 |
2016-09-23 |
제넨테크, 인크. |
알츠하이머 질환을 치료하는 방법
|
AU2015213741B2
(en)
|
2014-02-08 |
2020-10-08 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
US9518121B2
(en)
|
2014-02-12 |
2016-12-13 |
Genentech, Inc. |
Anti-Jagged1 antibodies and methods of use
|
CA2939507A1
(en)
|
2014-02-14 |
2015-08-20 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
|
DK3107562T3
(da)
|
2014-02-19 |
2019-12-16 |
Bioasis Technologies Inc |
P97-ids-fusionsproteiner
|
PL3107575T3
(pl)
|
2014-02-21 |
2022-01-17 |
Sanofi Biotechnology |
Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
|
EA201691473A1
(ru)
|
2014-02-21 |
2016-12-30 |
Дженентек, Инк. |
Биспецифические анти-il-13/il-17 антитела и их применение
|
CN106414465B
(zh)
|
2014-02-28 |
2021-11-16 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
SI3116999T1
(sl)
|
2014-03-14 |
2021-12-31 |
F. Hoffmann - La Roche Ag |
Postopki in sestavki za izločanje heterolognih polipeptidov
|
KR20220157516A
(ko)
|
2014-03-17 |
2022-11-29 |
사노피 바이오테크놀로지 |
심혈관 위험을 감소시키는 방법
|
EP3119811B1
(en)
|
2014-03-21 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
CA2942697A1
(en)
|
2014-03-21 |
2015-09-24 |
Lynn Macdonald |
Non-human animals that make single domain binding proteins
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
JP6666262B2
(ja)
|
2014-04-02 |
2020-03-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体の軽鎖誤対合を検出するための方法
|
WO2015153912A1
(en)
|
2014-04-03 |
2015-10-08 |
Igm Biosciences, Inc. |
Modified j-chain
|
AU2015247459A1
(en)
|
2014-04-18 |
2016-10-27 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
CA2943890A1
(en)
|
2014-05-01 |
2015-11-05 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
SG10202002187WA
(en)
|
2014-05-19 |
2020-04-29 |
Regeneron Pharma |
Genetically modified non-human animals expressing human epo
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
RU2648166C1
(ru)
*
|
2014-05-30 |
2018-03-22 |
Регенерон Фармасьютикалз, Инк. |
Животные, содержащие гуманизированную дипептидилпептидазу iv (dpp4)
|
DK3152312T3
(da)
*
|
2014-06-06 |
2020-04-06 |
Regeneron Pharma |
Fremgangsmåder og sammensætninger til modifikation af et mållocus
|
EP3155015A1
(en)
|
2014-06-11 |
2017-04-19 |
F. Hoffmann-La Roche AG |
Anti-lgr5 antibodies and uses thereof
|
CN107135646B
(zh)
|
2014-06-13 |
2022-03-15 |
阿塞勒隆制药公司 |
用于治疗溃疡的方法和组合物
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
PT3354732T
(pt)
|
2014-06-23 |
2020-04-02 |
Regeneron Pharma |
Montagem de dna mediada por nuclease
|
DK3161128T3
(en)
|
2014-06-26 |
2018-11-05 |
Regeneron Pharma |
METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
CA2954687A1
(en)
|
2014-07-10 |
2016-01-14 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
US9914774B2
(en)
|
2014-07-11 |
2018-03-13 |
Genentech, Inc. |
Notch pathway inhibition
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
EP3753575A1
(en)
|
2014-07-16 |
2020-12-23 |
Sanofi Biotechnology |
Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9
|
EP3677277A1
(en)
|
2014-07-16 |
2020-07-08 |
Sanofi Biotechnology |
Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
|
JP6705807B2
(ja)
|
2014-08-15 |
2020-06-03 |
エーダイニクス インコーポレイテッド |
疼痛を治療するためのオリゴヌクレオチドデコイ
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
AU2015317899A1
(en)
|
2014-09-16 |
2017-04-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies and uses thereof
|
MX2017003472A
(es)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-her2.
|
RU2017113134A
(ru)
|
2014-09-19 |
2018-10-19 |
Регенерон Фармасьютикалз, Инк. |
Химерные антигенные рецепторы
|
KR102576368B1
(ko)
|
2014-09-23 |
2023-09-08 |
리제너론 파마슈티칼스 인코포레이티드 |
항-il-25 항체 및 그것의 사용
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
EP3207124B1
(en)
|
2014-10-15 |
2019-06-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
SG11201703448QA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
CA2960797A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
CR20170240A
(es)
|
2014-11-10 |
2018-04-03 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos
|
EP3875481A1
(en)
|
2014-11-14 |
2021-09-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
IL294554B2
(en)
|
2014-11-14 |
2023-11-01 |
Regeneron Pharma |
Methods for treating chronic sinusitis with nasal polyps by adding an IL-4R antagonist
|
ES2939555T3
(es)
|
2014-11-14 |
2023-04-24 |
Regeneron Pharma |
Método para generar anticuerpos de alta afinidad
|
SG11201703605QA
(en)
|
2014-11-17 |
2017-06-29 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
NZ731962A
(en)
|
2014-11-21 |
2022-07-01 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification using paired guide rnas
|
RS63410B1
(sr)
|
2014-11-24 |
2022-08-31 |
Regeneron Pharma |
Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
|
JP6554280B2
(ja)
*
|
2014-11-28 |
2019-07-31 |
株式会社デンソーテン |
データ処理装置、画像処理方法、及び、プログラム
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
CR20170230A
(es)
|
2014-12-05 |
2017-11-07 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
EP3233120A4
(en)
|
2014-12-19 |
2018-05-30 |
Monash University |
Il-21 antibodies
|
WO2016100819A1
(en)
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
TWI701258B
(zh)
|
2014-12-19 |
2020-08-11 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
MY183415A
(en)
|
2014-12-19 |
2021-02-18 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
US20180016327A1
(en)
|
2015-01-22 |
2018-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
A Combination of Two or More Anti-C5 Antibodies and Methods of Use
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
EP3253778A1
(en)
|
2015-02-05 |
2017-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
CA2976074A1
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
WO2016131058A1
(en)
|
2015-02-13 |
2016-08-18 |
Biommune Technologies Inc. |
Antibodies to l-type voltage gated channels and related methods
|
TWI719967B
(zh)
|
2015-03-09 |
2021-03-01 |
美商艾澤西公司 |
結合至flt3蛋白之抗體藥物結合物(adc)
|
MX2017011918A
(es)
|
2015-03-16 |
2018-05-22 |
Regeneron Pharma |
Animal no humano que muestra una disminucion de la funcion de las motoneuronas superiores e inferiores y de la percepcion sensorial.
|
JP2018511797A
(ja)
|
2015-03-16 |
2018-04-26 |
ジェネンテック, インコーポレイテッド |
IL−13の検出方法及び定量方法並びにTh2関連疾患の診断及び治療における使用
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
DK3271389T3
(da)
|
2015-03-20 |
2020-04-27 |
Us Health |
Neutraliserende antistoffer mod gp120 og anvendelse deraf
|
KR20230164243A
(ko)
|
2015-03-23 |
2023-12-01 |
조운스 테라퓨틱스, 인크. |
Icos에 대한 항체
|
JP6948950B2
(ja)
|
2015-03-27 |
2021-10-13 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
メイタンシノイド誘導体、そのコンジュゲート、及び使用方法
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
HRP20231039T1
(hr)
|
2015-04-06 |
2023-12-22 |
Regeneron Pharmaceuticals, Inc. |
Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja
|
CN115073610A
(zh)
|
2015-04-06 |
2022-09-20 |
阿塞勒隆制药公司 |
Alk7:actriib异多聚体和其用途
|
RS62546B1
(sr)
|
2015-04-07 |
2021-12-31 |
Alector Llc |
Antitela protiv sortilina i postupci za njihovu upotrebu
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
EP4248740A3
(en)
|
2015-04-13 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Humanized sirpa-il15 knockin mice and methods of use thereof
|
CN115932273A
(zh)
|
2015-04-24 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
US20160346387A1
(en)
|
2015-05-11 |
2016-12-01 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
RU2725737C2
(ru)
|
2015-05-29 |
2020-07-03 |
Регенерон Фармасьютикалс, Инк. |
Животные, отличные от человека, с нарушением в локусе c9orf72
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2016196343A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CN107849124B
(zh)
|
2015-06-05 |
2021-09-24 |
基因泰克公司 |
抗tau抗体及使用方法
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体を使用して癌を治療する方法
|
CA2988420A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
EP3307771A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
US10017577B2
(en)
|
2015-06-15 |
2018-07-10 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
RU2748943C2
(ru)
|
2015-06-16 |
2021-06-02 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP3310815A1
(en)
|
2015-06-17 |
2018-04-25 |
F. Hoffmann-La Roche AG |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
JP2018524312A
(ja)
|
2015-06-17 |
2018-08-30 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び使用方法
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
BR112017027736A2
(pt)
|
2015-06-29 |
2018-10-09 |
Genentech Inc |
anticorpo anti-cd20 tipo ii para uso no transplante de órgãos
|
EP3319936A4
(en)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CN108348578B
(zh)
|
2015-08-04 |
2022-08-09 |
阿塞勒隆制药公司 |
用于治疗骨髓增生性病症的方法
|
KR20180030917A
(ko)
|
2015-08-05 |
2018-03-26 |
얀센 바이오테크 인코포레이티드 |
항-cd154 항체 및 그의 사용 방법
|
TW201713690A
(zh)
|
2015-08-07 |
2017-04-16 |
再生元醫藥公司 |
抗angptl8抗體及其用途
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
MA42657A
(fr)
|
2015-08-18 |
2018-06-27 |
Regeneron Pharma |
Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
|
IL257411B2
(en)
|
2015-08-24 |
2024-05-01 |
Trianni Inc |
Improved production of immunoglobulins
|
TW202342532A
(zh)
|
2015-09-18 |
2023-11-01 |
日商中外製藥股份有限公司 |
Il-8結合抗體及其用途
|
IL257565B1
(en)
|
2015-09-23 |
2024-04-01 |
Genentech Inc |
Improved variants of anti-VEGF antibodies
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
US10017572B2
(en)
|
2015-09-25 |
2018-07-10 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
US11639389B2
(en)
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
EP3355913A1
(en)
|
2015-09-30 |
2018-08-08 |
IGM Biosciences A/S |
Binding molecules with modified j-chain
|
CA3000400A1
(en)
|
2015-09-30 |
2017-04-06 |
Janssen Biotech, Inc. |
Agonistic antibodies specifically binding human cd40 and methods of use
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MY190297A
(en)
|
2015-10-02 |
2022-04-12 |
Hoffmann La Roche |
Anti-pd1 antibodies and methods of use
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
BR112018007703A2
(pt)
|
2015-10-30 |
2018-11-06 |
Genentech Inc |
anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
|
MX2018005550A
(es)
|
2015-11-03 |
2019-07-18 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a tim-3 y sus usos.
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
AU2016359695A1
(en)
|
2015-11-23 |
2018-06-14 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
WO2017095939A1
(en)
|
2015-12-03 |
2017-06-08 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
US20180355043A1
(en)
|
2015-12-17 |
2018-12-13 |
Janssen Biotech, Inc. |
Antibodies Specifically Binding HLA-DR and Their Uses
|
PE20240365A1
(es)
|
2015-12-18 |
2024-03-04 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
CN114128676A
(zh)
|
2016-01-13 |
2022-03-04 |
瑞泽恩制药公司 |
具有包括改造的多样性簇的免疫球蛋白重链可变区的非人动物及其用途
|
CN108602883A
(zh)
|
2016-01-20 |
2018-09-28 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
CN108779127B
(zh)
|
2016-01-25 |
2022-07-05 |
里珍纳龙药品有限公司 |
美登素类化合物衍生物、其偶联物和使用方法
|
JP6929877B2
(ja)
|
2016-02-04 |
2021-09-01 |
トリアニ・インコーポレイテッドTrianni, Inc. |
免疫グロブリン産生の増強
|
MA44242A
(fr)
*
|
2016-02-16 |
2018-12-26 |
Regeneron Pharma |
Animaux non humains ayant un gène de kynuréninase mutant
|
KR20180108840A
(ko)
|
2016-02-17 |
2018-10-04 |
리제너론 파아마슈티컬스, 인크. |
Angptl3의 억제제를 투여함으로써 죽상 동맥경화증을 치료하거나 예방하기 위한 방법
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
EP3423157A1
(en)
|
2016-03-03 |
2019-01-09 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
|
CA3016552A1
(en)
|
2016-03-15 |
2017-09-21 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
WO2017172958A1
(en)
|
2016-03-29 |
2017-10-05 |
Regeneron Pharmaceuticals, Inc. |
Genetic variant-phenotype analysis system and methods of use
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
RS62769B1
(sr)
|
2016-04-08 |
2022-01-31 |
Regeneron Pharma |
Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
CN109069641A
(zh)
|
2016-04-28 |
2018-12-21 |
瑞泽恩制药公司 |
用于治疗家族性高胆固醇血症患者的方法
|
EP3889175A1
(en)
|
2016-05-02 |
2021-10-06 |
F. Hoffmann-La Roche AG |
The contorsbody - a single chain target binder
|
EP3455252B1
(en)
|
2016-05-11 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Modified anti-tenascin antibodies and methods of use
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
RU2021106817A
(ru)
|
2016-05-20 |
2021-04-06 |
Регенерон Фармасьютикалс, Инк. |
Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
CN116458475A
(zh)
|
2016-06-03 |
2023-07-21 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|
WO2017214089A1
(en)
|
2016-06-06 |
2017-12-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing antibodies with human lambda light chains
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
MX2018014679A
(es)
|
2016-06-06 |
2019-04-29 |
Hoffmann La Roche |
Proteinas de fusion para oftalmologia con retencion ocular aumentada.
|
GB201610162D0
(en)
|
2016-06-10 |
2016-07-27 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
KR102534895B1
(ko)
|
2016-06-14 |
2023-05-24 |
리제너론 파아마슈티컬스, 인크. |
항-c5 항체 및 이의 용도
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
TWI767915B
(zh)
|
2016-06-27 |
2022-06-21 |
加州大學董事會 |
Ror-1與btk拮抗劑的組合
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
RS62011B1
(sr)
|
2016-07-15 |
2021-07-30 |
Acceleron Pharma Inc |
Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EA201990226A1
(ru)
|
2016-07-27 |
2019-08-30 |
Акселерон Фарма Инк. |
Способы и композиции для лечения миелофиброза
|
MX2018015721A
(es)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
|
EP3490373B1
(en)
|
2016-07-29 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
EP3282019A1
(en)
|
2016-08-09 |
2018-02-14 |
Medizinische Universität Wien |
Genotyping and treatment of cancer, in particular chronic lymphocytic leukemia
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
MA45919A
(fr)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
|
EP3497126A4
(en)
|
2016-08-12 |
2020-04-08 |
Janssen Biotech, Inc. |
ANTIBODIES OF FC MODIFIED ANTI-TNFR SUPERFAMILY HAVING IMPROVED AGONIST ACTIVITY AND METHODS OF USE THEREOF
|
CN109641954A
(zh)
|
2016-08-29 |
2019-04-16 |
里珍纳龙药品有限公司 |
抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
US20190248920A1
(en)
|
2016-09-23 |
2019-08-15 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
RU2752785C2
(ru)
|
2016-09-23 |
2021-08-04 |
Дженентек, Инк. |
Применение антагонистов il-13 для лечения атопического дерматита
|
KR102294755B1
(ko)
|
2016-09-30 |
2021-08-31 |
리제너론 파마슈티칼스 인코포레이티드 |
C9orf72 유전자좌에서 헥사뉴클레오티드 반복 확장을 갖는 비인간 동물
|
JP2019529509A
(ja)
|
2016-10-05 |
2019-10-17 |
アクセレロン ファーマ インコーポレーテッド |
腎臓疾患を治療するための組成物および方法
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
JP2020503844A
(ja)
|
2016-10-21 |
2020-02-06 |
アディマブ, エルエルシー |
抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
|
US11479600B2
(en)
|
2016-10-21 |
2022-10-25 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
AU2017345786A1
(en)
|
2016-10-21 |
2019-05-23 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
CA3042171C
(en)
*
|
2016-10-31 |
2021-07-20 |
National University Corporation Tottori University |
Human antibody-producing non-human animal and method for preparing human antibody using same
|
EP3535298B1
(en)
|
2016-11-02 |
2021-09-08 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
RS60886B1
(sr)
|
2016-11-04 |
2020-11-30 |
Regeneron Pharma |
Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca
|
JP7330101B2
(ja)
|
2016-11-08 |
2023-08-21 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
ステロイド及びそのタンパク質コンジュゲート
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
AU2017363143B2
(en)
|
2016-11-17 |
2022-07-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating obesity with anti-ANGPTL8 antibodies
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
US11773163B2
(en)
|
2016-11-21 |
2023-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
MA45890B2
(fr)
|
2016-11-29 |
2022-10-31 |
Regeneron Pharma |
Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
|
KR102480773B1
(ko)
|
2016-11-30 |
2022-12-23 |
크로다 인터내셔날 피엘씨 |
수성 결합제 시스템, 코팅 조성물 및 코팅
|
KR20240035636A
(ko)
|
2016-12-07 |
2024-03-15 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
WO2018106781A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc |
Anti-tau antibodies and methods of use
|
EP3556773A4
(en)
|
2016-12-13 |
2020-08-19 |
Astellas Pharma Inc. |
ANTIBODIES TO HUMAN CD73
|
WO2018114878A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
CA3044920C
(en)
|
2016-12-21 |
2022-06-28 |
Roberto Falkenstein |
In vitro glycoengineering of antibodies
|
CN110088292A
(zh)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
EP3558347A1
(en)
|
2016-12-22 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
JP7007734B2
(ja)
*
|
2016-12-27 |
2022-02-10 |
国立大学法人群馬大学 |
条件付きノックアウト動物の製造方法
|
TW202311284A
(zh)
|
2017-01-03 |
2023-03-16 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素a毒素之人類抗體
|
EP3571301A1
(en)
|
2017-01-23 |
2019-11-27 |
Regeneron Pharmaceuticals, Inc. |
Hsd17b13 variants and uses thereof
|
US10713373B2
(en)
*
|
2017-02-09 |
2020-07-14 |
Lifesite, Inc. |
Computing system with information storage mechanism and method of operation thereof
|
AU2018219909A1
(en)
|
2017-02-10 |
2019-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
MY197534A
(en)
|
2017-02-10 |
2023-06-21 |
Genentech Inc |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
MX2019011141A
(es)
|
2017-03-22 |
2019-11-05 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
|
MX2019011769A
(es)
|
2017-04-03 |
2019-11-07 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1.
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
HRP20221254T1
(hr)
|
2017-04-03 |
2022-12-23 |
F. Hoffmann - La Roche Ag |
Imunokonjugati protutijela anti-pd-1 s mutacijskim polipeptidom interleukina-2 ili interleukina-15
|
LT3606954T
(lt)
|
2017-04-05 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Anti-lag3 antikūnai
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
CA3060514A1
(en)
|
2017-04-20 |
2018-10-25 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
WO2018195472A1
(en)
|
2017-04-21 |
2018-10-25 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
KR20200003843A
(ko)
|
2017-04-27 |
2020-01-10 |
테사로, 인코포레이티드 |
림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
|
EP3625251A1
(en)
|
2017-05-15 |
2020-03-25 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
MX2019013690A
(es)
|
2017-05-18 |
2020-01-27 |
Regeneron Pharma |
Conjugados de farmaco-proteina con ciclodextrina.
|
US10793624B2
(en)
|
2017-06-01 |
2020-10-06 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to Bet v 1 and methods of use thereof
|
UA128035C2
(uk)
|
2017-06-05 |
2024-03-20 |
Янссен Байотек, Інк. |
Антитіло, що специфічно зв'язує pd-1, і спосіб його застосування
|
WO2018224951A2
(en)
|
2017-06-05 |
2018-12-13 |
Janssen Biotech, Inc. |
Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
US10806780B2
(en)
|
2017-06-28 |
2020-10-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
US11414478B2
(en)
|
2017-07-21 |
2022-08-16 |
Trianni, Inc. |
Single chain VH and heavy chain antibodies
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
US11174322B2
(en)
|
2017-07-24 |
2021-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat HCMV related diseases
|
CA3070796A1
(en)
|
2017-07-24 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd8 antibodies and uses thereof
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
JP7299160B2
(ja)
|
2017-08-03 |
2023-06-27 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
EP3679070A1
(en)
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
AR113142A1
(es)
|
2017-09-29 |
2020-01-29 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
|
MX2020002976A
(es)
|
2017-09-29 |
2020-07-24 |
Regeneron Pharma |
Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas.
|
DK3476942T3
(da)
|
2017-10-27 |
2022-04-19 |
Trianni Inc |
Lange kimlinje-dh-gener og antistoffer med lang hcdr3
|
US11034768B2
(en)
|
2017-10-30 |
2021-06-15 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an IL-4R antagonist
|
CN111278856A
(zh)
|
2017-11-01 |
2020-06-12 |
豪夫迈·罗氏有限公司 |
三Fab-康特斯体
|
CN111295392A
(zh)
|
2017-11-01 |
2020-06-16 |
豪夫迈·罗氏有限公司 |
Compbody–多价靶结合物
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
WO2019108662A1
(en)
|
2017-11-30 |
2019-06-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-trkb monoclonal antibodies and methods of use
|
TWI827567B
(zh)
|
2017-12-05 |
2024-01-01 |
美商再生元醫藥公司 |
具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
|
MX2020006113A
(es)
|
2017-12-13 |
2020-08-24 |
Regeneron Pharma |
Combinaciones de anticuerpos anti-c5 y usos de las mismas.
|
WO2019126194A1
(en)
|
2017-12-18 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
Angptl8 assay and uses thereof
|
MA51302A
(fr)
|
2017-12-21 |
2021-03-31 |
Hoffmann La Roche |
Anticorps se liant à hla-a2/wt1
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
US10723798B2
(en)
|
2017-12-22 |
2020-07-28 |
Jounce Therapeutics, Inc. |
Antibodies to LILRB2
|
CA3078849A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Tigitに対する単一ドメイン抗体及びその変異体
|
WO2019133512A1
(en)
|
2017-12-29 |
2019-07-04 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
EP3737420A2
(en)
|
2018-01-08 |
2020-11-18 |
Regeneron Pharmaceuticals, Inc. |
Steroids and antibody-conjugates thereof
|
SG11202004233UA
(en)
|
2018-01-15 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against pd-1
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
CA3088194A1
(en)
|
2018-01-26 |
2019-08-01 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to influenza hemagglutinin
|
RS61825B1
(sr)
|
2018-01-26 |
2021-06-30 |
Regeneron Pharma |
Anti-tmprss2 antitela i fragmenti koji vezuju antigen
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
PE20211116A1
(es)
|
2018-02-08 |
2021-06-23 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso
|
CA3088557C
(en)
|
2018-02-09 |
2024-02-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
EP3759141A1
(en)
|
2018-02-26 |
2021-01-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
KR20200129127A
(ko)
|
2018-03-06 |
2020-11-17 |
사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 |
심혈관 위험을 감소시키기 위한 pcsk9 억제제의 용도
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
MX2020009989A
(es)
|
2018-03-24 |
2020-10-14 |
Regeneron Pharma |
Animales no humanos geneticamente modificados para generar anticuerpos terapeuticos contra complejos peptidos-mhc, metodos de elaboracion y usos de estos.
|
US11747340B2
(en)
|
2018-03-24 |
2023-09-05 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying HLA-associated tumor peptides
|
EP3774893A1
(en)
|
2018-03-26 |
2021-02-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-pfrh5 antibodies and antigen-binding fragments thereof
|
EP3772926A1
(en)
|
2018-03-26 |
2021-02-17 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
SG11202009542PA
(en)
|
2018-03-29 |
2020-10-29 |
Genentech Inc |
Modulating lactogenic activity in mammalian cells
|
JP7346790B2
(ja)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Lag‐3に対する単一ドメイン抗体およびその使用
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
WO2019213384A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
WO2019217591A1
(en)
|
2018-05-09 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-msr1 antibodies and methods of use thereof
|
US11603405B2
(en)
|
2018-05-24 |
2023-03-14 |
Janssen Biotech, Inc. |
Anti-CD3 antibodies and uses thereof
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
US11866499B2
(en)
|
2018-05-24 |
2024-01-09 |
Janssen Biotech, Inc. |
Monospecific and multispecific anti-TMEFF2 antibodies and their uses
|
MA52753A
(fr)
|
2018-05-25 |
2021-04-21 |
Alector Llc |
Anticorps anti-sirpa et leurs procédés d'utilisation
|
AU2019278875A1
(en)
|
2018-05-31 |
2020-10-22 |
Glyconex Inc. |
Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens
|
AU2019275737A1
(en)
|
2018-06-01 |
2021-01-21 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
US20190370254A1
(en)
|
2018-06-01 |
2019-12-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for sparse vector-based matrix transformations
|
LT3629720T
(lt)
|
2018-06-14 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Gyvūnai, išskyrus žmogų, gebantys vykdyti imunoglobulino sunkiosios grandinės koduojančių sekų dh-dh pertvarkymą
|
CN112437682A
(zh)
|
2018-06-19 |
2021-03-02 |
里珍纳龙药品有限公司 |
抗因子XII/XIIa抗体和其用途
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
CA3099176A1
(en)
|
2018-06-29 |
2020-01-02 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
WO2020014358A1
(en)
|
2018-07-10 |
2020-01-16 |
Regeneron Pharmaceuticals, Inc. |
Modifying binding molecules to minimize pre-existing interactions
|
HUE061841T2
(hu)
|
2018-07-13 |
2023-08-28 |
Alector Llc |
Anti-sortilin antitestek és felhasználásuk módszerei
|
WO2020018503A2
(en)
|
2018-07-16 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-il36r antibodies
|
WO2020018584A2
(en)
|
2018-07-17 |
2020-01-23 |
Humabs Biomed Sa |
Antibodies against campylobacter species
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
US11155606B2
(en)
|
2018-07-24 |
2021-10-26 |
Medimmune, Llc |
Antibody directed against S. aureus clumping factor a (ClfA)
|
MX2021001549A
(es)
|
2018-08-10 |
2021-04-13 |
Regeneron Pharma |
Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
|
JP6718560B1
(ja)
|
2018-08-10 |
2020-07-08 |
中外製薬株式会社 |
抗cd137抗原結合分子およびその使用
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
WO2020047029A1
(en)
|
2018-08-29 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having rheumatoid arthritis
|
WO2020047374A1
(en)
|
2018-08-31 |
2020-03-05 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
US20220053741A1
(en)
|
2018-09-13 |
2022-02-24 |
Regeneron Pharmaceuticals, Inc. |
Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
PL3857230T3
(pl)
|
2018-09-21 |
2023-10-16 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
|
BR112021006622A2
(pt)
|
2018-10-09 |
2021-07-20 |
Medimmune, Llc |
combinações de anticorpos anti-staphylococcus aureus
|
TW202028244A
(zh)
|
2018-10-09 |
2020-08-01 |
美商建南德克公司 |
用於確定突觸形成之方法及系統
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
BR112021004329A2
(pt)
|
2018-10-23 |
2021-08-03 |
Regeneron Pharmaceuticals, Inc. |
anticorpos anti-npr1 e usos dos mesmos
|
CA3115110A1
(en)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
WO2020090892A1
(ja)
|
2018-10-31 |
2020-05-07 |
アステラス製薬株式会社 |
抗ヒトFn14抗体
|
WO2020094609A1
(en)
|
2018-11-06 |
2020-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
AU2019384790A1
(en)
|
2018-11-21 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
WO2020120786A1
(en)
|
2018-12-14 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
GB201820554D0
(en)
|
2018-12-17 |
2019-01-30 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
SG11202105189RA
(en)
|
2018-12-20 |
2021-06-29 |
Regeneron Pharma |
Nuclease-mediated repeat expansion
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
CA3120474A1
(en)
|
2018-12-21 |
2020-06-25 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
KR20210116525A
(ko)
|
2019-01-14 |
2021-09-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법
|
CN113329763A
(zh)
|
2019-01-22 |
2021-08-31 |
豪夫迈·罗氏有限公司 |
免疫球蛋白a抗体以及制备和使用方法
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
WO2020160242A1
(en)
|
2019-02-01 |
2020-08-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-il2 receptor gamma antigen-binding proteins
|
AU2020223205A1
(en)
|
2019-02-12 |
2021-08-05 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
WO2020164561A1
(en)
|
2019-02-15 |
2020-08-20 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Process for preparing antibody-drug conjugates with improved homogeneity
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
JP2022521358A
(ja)
|
2019-02-18 |
2022-04-06 |
バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド |
ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
|
BR112021016173A2
(pt)
|
2019-02-22 |
2021-11-03 |
Regeneron Pharma |
Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
|
KR20210133237A
(ko)
|
2019-02-27 |
2021-11-05 |
제넨테크, 인크. |
항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
|
MX2021010441A
(es)
|
2019-03-01 |
2021-09-21 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
|
MX2021010565A
(es)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
|
ES2923629T3
(es)
|
2019-04-04 |
2022-09-29 |
Regeneron Pharma |
Métodos para la introducción sin cicatrices de modificaciones dirigidas en vectores de direccionamiento
|
WO2020206139A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
MA55615A
(fr)
|
2019-04-10 |
2022-02-16 |
Regeneron Pharma |
Anticorps humains qui se lient au ret et leurs procédés d'utilisation
|
AU2020258384A1
(en)
|
2019-04-15 |
2021-11-04 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
|
MX2021012767A
(es)
|
2019-04-19 |
2021-11-18 |
Janssen Biotech Inc |
Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
|
JP2022529154A
(ja)
|
2019-04-19 |
2022-06-17 |
ジェネンテック, インコーポレイテッド |
抗mertk抗体及びその使用方法
|
KR20220004028A
(ko)
|
2019-04-26 |
2022-01-11 |
알로젠 테라퓨틱스 인코포레이티드 |
동종 car t 세포를 제조하는 방법
|
SG11202111255YA
(en)
|
2019-05-01 |
2021-11-29 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-33 antagonist
|
JP2022530674A
(ja)
|
2019-05-03 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
抗pd-l1抗体を用いたがんの処置方法
|
US20220227853A1
(en)
|
2019-05-03 |
2022-07-21 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
KR20220016869A
(ko)
|
2019-06-04 |
2022-02-10 |
리제너론 파마슈티칼스 인코포레이티드 |
베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
|
BR112021023683A2
(pt)
|
2019-06-05 |
2022-02-01 |
Regeneron Pharma |
Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento
|
KR20220017939A
(ko)
|
2019-06-07 |
2022-02-14 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 알부민 좌위를 포함하는 비-인간 동물
|
US20200392229A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
BR112021023335A2
(pt)
|
2019-06-11 |
2022-01-04 |
Regeneron Pharma |
Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
|
WO2020251924A1
(en)
|
2019-06-12 |
2020-12-17 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to bone morphogenetic protein 6
|
EP3986933A1
(en)
|
2019-06-21 |
2022-04-27 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
CN113993547B
(zh)
|
2019-06-21 |
2024-04-26 |
瑞泽恩制药公司 |
结合muc16和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
|
AU2019452577B2
(en)
|
2019-06-29 |
2023-08-24 |
Hangzhou Dac Biotech Co., Ltd. |
Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor
|
CN114554841B
(zh)
|
2019-07-01 |
2024-06-11 |
特里安尼公司 |
转基因哺乳动物及其使用方法
|
JP2022538886A
(ja)
|
2019-07-01 |
2022-09-06 |
トリアニ・インコーポレイテッド |
トランスジェニック哺乳動物およびその使用法
|
EP3994169A1
(en)
|
2019-07-02 |
2022-05-11 |
F. Hoffmann-La Roche AG |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
CN115175700A
(zh)
|
2019-07-16 |
2022-10-11 |
赛诺菲生物技术公司 |
用于通过施用il-4r拮抗剂治疗或预防哮喘的方法
|
PE20220649A1
(es)
|
2019-07-26 |
2022-04-28 |
Janssen Biotech Inc |
Proteinas que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos
|
JP2022542964A
(ja)
|
2019-07-31 |
2022-10-07 |
アレクトル エルエルシー |
抗ms4a4a抗体、及びその使用方法
|
CA3144524A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
SG11202113310UA
(en)
|
2019-08-05 |
2021-12-30 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
KR20220042217A
(ko)
|
2019-08-05 |
2022-04-04 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
|
CA3149494A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
WO2021030657A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Materials and methods for improved single chain variable fragments
|
DK3785536T3
(da)
|
2019-08-28 |
2022-03-28 |
Trianni Inc |
Adam6-knockin-mus
|
AU2020345913A1
(en)
|
2019-09-12 |
2022-02-24 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
CN114423791A
(zh)
|
2019-09-18 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
|
CR20220149A
(es)
|
2019-09-20 |
2022-05-23 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa
|
WO2021057978A1
(zh)
|
2019-09-27 |
2021-04-01 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
CN114450304B
(zh)
|
2019-09-27 |
2023-12-12 |
国家医疗保健研究所 |
抗苗勒管抑制物质抗体及其用途
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
EP4034160A1
(en)
|
2019-09-27 |
2022-08-03 |
Janssen Biotech, Inc. |
Anti-ceacam antibodies and uses thereof
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
WO2021066869A1
(en)
|
2019-10-04 |
2021-04-08 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
CA3153880A1
(en)
|
2019-10-18 |
2020-06-09 |
Juana Elva HERNANDEZ MONTALVO |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
KR20220088446A
(ko)
|
2019-10-28 |
2022-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
항-헤마글루티닌 항체 및 이의 사용 방법
|
AU2020378330A1
(en)
|
2019-11-06 |
2022-05-12 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
BR112022008172A2
(pt)
|
2019-11-15 |
2022-07-12 |
Hoffmann La Roche |
Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
|
BR112022009598A2
(pt)
|
2019-11-18 |
2022-08-16 |
Janssen Biotech Inc |
Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
|
EP4061944A1
(en)
|
2019-11-22 |
2022-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
IL293282A
(en)
|
2019-11-25 |
2022-07-01 |
Mabloc Llc |
Yellow fever antiviral antibodies and methods of making and using them
|
AU2020395122A1
(en)
|
2019-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Peptide-MHC II protein constructs and uses thereof
|
KR20220110553A
(ko)
|
2019-12-06 |
2022-08-08 |
사노피 바이오테크놀로지 |
Il-33 길항제를 투여하여 copd를 치료하는 방법
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
CA3161037A1
(en)
|
2019-12-09 |
2021-06-17 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
US20230272112A1
(en)
|
2019-12-10 |
2023-08-31 |
Regeneron Pharmaceuticals, Inc. |
Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
|
KR20220127252A
(ko)
|
2019-12-13 |
2022-09-19 |
알렉터 엘엘씨 |
항-mertk 항체 및 이의 사용 방법
|
IL293423A
(en)
|
2019-12-13 |
2022-07-01 |
Genentech Inc |
Anti-ly6g6d antibodies and methods of use
|
CA3161390A1
(en)
|
2019-12-18 |
2021-06-24 |
Tina WEINZIERL |
Antibodies binding to hla-a2/mage-a4
|
JP2023508023A
(ja)
|
2019-12-20 |
2023-02-28 |
ハドソン インスティチュート オブ メディカル リサーチ |
Cxcl10結合タンパク質及びその使用
|
KR20220119446A
(ko)
|
2019-12-23 |
2022-08-29 |
사노피 바이오테크놀로지 |
Il-33 길항제 및/또는 il-4r 길항제를 투여하여 알레르기성 천식을 치료 또는 예방하는 방법
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
BR112022013481A2
(pt)
|
2020-01-08 |
2022-09-13 |
Regeneron Pharma |
Uso de aminoácidos para aumentar o sinal em análises espectro de massa
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
JP2023511956A
(ja)
|
2020-01-24 |
2023-03-23 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
タンパク質-抗ウイルス化合物コンジュゲート
|
WO2021154764A1
(en)
|
2020-01-27 |
2021-08-05 |
Regeneron Pharmaceuticals, Inc. |
Tandem mass tag multiplexed quantitation of post-translational modifications of proteins
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023511626A
(ja)
|
2020-01-28 |
2023-03-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化pnpla3遺伝子座を含む非ヒト動物および使用方法
|
AU2021214764A1
(en)
|
2020-01-30 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Platform for native liquid chromatography-mass spectrometry
|
CN115210574A
(zh)
|
2020-01-31 |
2022-10-18 |
瑞泽恩制药公司 |
通过液相色谱-质谱法进行高置信度化合物鉴定
|
CN116650628A
(zh)
|
2020-01-31 |
2023-08-29 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
CN115698057A
(zh)
|
2020-02-03 |
2023-02-03 |
维尔生物科技有限公司 |
抗sars-cov-2的抗体和其使用方法
|
EP3862023A1
(en)
|
2020-02-05 |
2021-08-11 |
Hangzhou DAC Biotech Co, Ltd |
Conjugates of cell-binding molecules with cytotoxic agents
|
US20230081547A1
(en)
|
2020-02-07 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
KR20220140503A
(ko)
|
2020-02-10 |
2022-10-18 |
리제너론 파마슈티칼스 인코포레이티드 |
항-tmprss2 항체 및 항원 결합 단편
|
US20230312704A1
(en)
|
2020-02-10 |
2023-10-05 |
Shanghai Escugen Biotechnology Co., Ltd. |
Cldn18.2 antibody and use thereof
|
WO2021160155A1
(zh)
|
2020-02-10 |
2021-08-19 |
上海诗健生物科技有限公司 |
密蛋白18.2的抗体及其用途
|
WO2021163170A1
(en)
|
2020-02-11 |
2021-08-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and uses thereof
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
CN115087488A
(zh)
|
2020-02-14 |
2022-09-20 |
震动疗法股份有限公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
LT3872091T
(lt)
|
2020-02-26 |
2023-10-10 |
Vir Biotechnology, Inc. |
Antikūnai prieš sars-cov-2
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
KR20220145859A
(ko)
|
2020-02-28 |
2022-10-31 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물, 다중 특이적 항체 및 그 용도
|
BR112022018176A2
(pt)
|
2020-03-13 |
2022-12-06 |
Janssen Biotech Inc |
Materiais e métodos para ligação de siglec-3/cd33
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
BR112022018657A2
(pt)
|
2020-03-19 |
2022-11-01 |
Genentech Inc |
Anticorpos, ácido nucleico, célula hospedeira, imunoconjugado, formulação farmacêutica, usos de um anticorpo, métodos de produção de um anticorpo e de tratamento de um indivíduo, métodos para inibir a sinalização de smad e para diagnosticar um indivíduo como tendo ssc e kit
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
CR20220489A
(es)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Agentes de fijación a tie2 y métodos de uso.
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
US20230102151A1
(en)
|
2020-03-27 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
JP2023519962A
(ja)
|
2020-03-31 |
2023-05-15 |
アレクトル エルエルシー |
抗mertk抗体及びその使用方法
|
JP2023519930A
(ja)
|
2020-04-01 |
2023-05-15 |
ユニバーシティ オブ ロチェスター |
インフルエンザh3n2ウイルスのヘマグルチニン(ha)およびノイラミニダーゼ(na)に対するモノクローナル抗体
|
MX2021004130A
(es)
|
2020-04-02 |
2021-06-15 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno.
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
US11885779B2
(en)
|
2020-04-14 |
2024-01-30 |
Regeneron Pharmaceuticals, Inc. |
Ultraviolet monitoring of chromatography performance by orthogonal partial least squares
|
EP4135846A1
(en)
|
2020-04-14 |
2023-02-22 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
AU2021256936A1
(en)
|
2020-04-15 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
IL297027A
(en)
|
2020-04-16 |
2022-12-01 |
Regeneron Pharma |
Diels-Alder compression methods
|
KR20230005172A
(ko)
|
2020-04-24 |
2023-01-09 |
에프. 호프만-라 로슈 아게 |
설프히드릴 화합물 및 이의 유도체를 사용한 효소 및 경로 조절
|
CA3175530A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
JP2023523480A
(ja)
|
2020-04-28 |
2023-06-06 |
ザ ロックフェラー ユニバーシティー |
中和抗sars-cov-2抗体およびその使用方法
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁(苏州)生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
EP4146690A1
(en)
|
2020-05-08 |
2023-03-15 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2
|
US20230181753A1
(en)
|
2020-05-12 |
2023-06-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
WO2021231366A1
(en)
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-glp1r antagonist antibodies and methods of use thereof
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
EP4153130A1
(en)
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
KR20230015965A
(ko)
|
2020-05-22 |
2023-01-31 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
|
AU2021282179A1
(en)
|
2020-05-26 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
|
MX2022014938A
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
|
US11787861B2
(en)
|
2020-05-29 |
2023-10-17 |
23Andme, Inc. |
Anti-CD200R1 antibodies and methods of use thereof
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
JP2023529842A
(ja)
|
2020-06-02 |
2023-07-12 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗cd93構築物およびその使用
|
KR20230018439A
(ko)
|
2020-06-02 |
2023-02-07 |
바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 |
공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
CN115697489A
(zh)
|
2020-06-08 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
抗hbv抗体及其使用方法
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
EP4165077A1
(en)
|
2020-06-12 |
2023-04-19 |
VIR Biotechnology, Inc. |
Antibody therapies for sars-cov-2 infection
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
JP2023532203A
(ja)
|
2020-06-18 |
2023-07-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アクチビンa抗体製剤及びその使用方法
|
JP2023531200A
(ja)
|
2020-06-18 |
2023-07-21 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体及びpd-1軸結合アンタゴニストを用いた治療
|
WO2021259880A1
(en)
|
2020-06-22 |
2021-12-30 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
JP2023541216A
(ja)
|
2020-06-25 |
2023-09-29 |
ヒューマブ カンパニー リミテッド |
ヘテロ接合型トランスジェニック動物
|
IL299207A
(en)
|
2020-07-01 |
2023-02-01 |
Regeneron Pharma |
Methods of allergy treatment using anti-BET V 1 antibodies
|
JP2023532764A
(ja)
|
2020-07-07 |
2023-07-31 |
エフ. ホフマン-ラ ロシュ アーゲー |
治療用タンパク質製剤の安定剤としての代替界面活性剤
|
KR20230038738A
(ko)
|
2020-07-13 |
2023-03-21 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
KR20230038735A
(ko)
|
2020-07-17 |
2023-03-21 |
제넨테크, 인크. |
항-notch2 항체 및 이용 방법
|
AU2021312225A1
(en)
|
2020-07-21 |
2023-02-16 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation of BRM and methods thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
US11827708B2
(en)
|
2020-07-29 |
2023-11-28 |
Janssen Biotech, Inc. |
Proteins comprising HLA-G antigen binding domains and their uses
|
US20220072127A1
(en)
|
2020-08-07 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with refractory hypercholesterolemia
|
CA3128035A1
(en)
|
2020-08-13 |
2022-02-13 |
Bioasis Technologies, Inc. |
Combination therapies for delivery across the blood brain barrier
|
WO2022046925A1
(en)
|
2020-08-26 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
WO2022056276A1
(en)
|
2020-09-11 |
2022-03-17 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
EP4211165A1
(en)
|
2020-09-14 |
2023-07-19 |
Ichnos Sciences SA |
Antibodies that bind to il1rap and uses thereof
|
AU2021339892A1
(en)
|
2020-09-14 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
EP4217385A2
(en)
|
2020-09-28 |
2023-08-02 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2
|
WO2022076289A1
(en)
|
2020-10-05 |
2022-04-14 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022075793A1
(ko)
|
2020-10-08 |
2022-04-14 |
주식회사 휴맵 |
인간화 면역글로불린 유전자좌를 포함하는 게놈을 가지는 형질전환 비인간-동물 제조방법
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
US20230416382A1
(en)
|
2020-10-14 |
2023-12-28 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
IL300024A
(en)
|
2020-10-20 |
2023-03-01 |
Hoffmann La Roche |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
|
KR20230095070A
(ko)
|
2020-10-22 |
2023-06-28 |
리제너론 파마슈티칼스 인코포레이티드 |
항-fgfr2 항체 및 이의 사용 방법
|
JP2023548034A
(ja)
|
2020-10-22 |
2023-11-15 |
ヤンセン バイオテツク,インコーポレーテツド |
デルタ様リガンド3(dll3)抗原結合ドメインを含むタンパク質及びその使用
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
JP7402381B2
(ja)
|
2020-11-04 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
TW202227481A
(zh)
|
2020-11-04 |
2022-07-16 |
美國洛克菲勒大學 |
中和抗sars-cov-2抗體
|
TW202225191A
(zh)
|
2020-11-04 |
2022-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
US20240002483A1
(en)
|
2020-11-16 |
2024-01-04 |
Hoffmann-La Roche Inc. |
Fab high mannose glycoforms
|
CR20230244A
(es)
|
2020-11-16 |
2023-07-12 |
Astellas Pharma Inc |
Anticuerpo biespecífico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8
|
WO2022109317A1
(en)
|
2020-11-23 |
2022-05-27 |
Vir Biotechnology, Inc. |
Anti-influenza antibodies and combinations thereof
|
MX2023005654A
(es)
|
2020-11-23 |
2023-07-31 |
Vir Biotechnology Inc |
Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza.
|
AU2021382620A1
(en)
|
2020-11-23 |
2023-06-15 |
Humabs Biomed Sa |
Antibodies against influenza a viruses
|
WO2022115486A1
(en)
|
2020-11-25 |
2022-06-02 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple betacoronaviruses
|
KR20230117169A
(ko)
|
2020-12-02 |
2023-08-07 |
알렉터 엘엘씨 |
항-소르틸린 항체의 사용 방법
|
IL303529A
(en)
|
2020-12-09 |
2023-08-01 |
Trianni Inc |
Heavy chain antibodies only
|
KR20230147048A
(ko)
|
2020-12-16 |
2023-10-20 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 Fc 알파 수용체를 발현하는 마우스
|
PE20240819A1
(es)
|
2020-12-17 |
2024-04-18 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
KR20230132468A
(ko)
|
2020-12-18 |
2023-09-15 |
리제너론 파아마슈티컬스, 인크. |
Npr1 작용제에 결합하는 면역글로불린 단백질
|
CN116745609A
(zh)
|
2020-12-20 |
2023-09-12 |
瑞泽恩制药公司 |
鉴定生物分子中乱序二硫键的方法
|
MX2023007401A
(es)
|
2020-12-23 |
2023-07-06 |
Regeneron Pharma |
Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
|
CN116635413A
(zh)
|
2020-12-23 |
2023-08-22 |
再生元制药公司 |
用于获得结合跨膜蛋白的抗体的方法和生产所述抗体的细胞
|
WO2022150605A1
(en)
|
2021-01-08 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
CA3207850A1
(en)
|
2021-01-13 |
2022-07-21 |
Astellas Pharma Inc. |
Multispecific antibody bonding to actriia, actriib, and fn14
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
WO2022159842A1
(en)
|
2021-01-25 |
2022-07-28 |
Vir Biotechnology, Inc. |
Antibody combination therapies for sars-cov-2 infection
|
US20220242943A1
(en)
|
2021-01-25 |
2022-08-04 |
Regeneron Pharmaceuticals, Inc. |
Anti- pdgf-b antibodies and methods of use for treating pulmonary arterial hypertension (pah)
|
BR112023015097A2
(pt)
|
2021-01-28 |
2023-10-03 |
Janssen Biotech Inc |
Proteínas de ligação a psma e usos das mesmas
|
AU2022220611A1
(en)
|
2021-02-09 |
2023-08-24 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
TW202246317A
(zh)
|
2021-02-09 |
2022-12-01 |
瑞士商休曼生物醫藥股份公司 |
針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
|
AU2022221297A1
(en)
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
WO2022184082A1
(en)
|
2021-03-03 |
2022-09-09 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
WO2022187863A1
(en)
|
2021-03-05 |
2022-09-09 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
WO2022197947A1
(en)
|
2021-03-18 |
2022-09-22 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
EP4314063A1
(en)
|
2021-03-23 |
2024-02-07 |
Alector LLC |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
AU2022242125A1
(en)
|
2021-03-24 |
2023-11-09 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
UY39683A
(es)
|
2021-03-24 |
2022-09-30 |
Janssen Biotech Inc |
Anticuerpo dirigido a cd22 y cd79b
|
EP4314049A1
(en)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7 constructs and uses thereof
|
AR125255A1
(es)
|
2021-04-02 |
2023-06-28 |
Regeneron Pharma |
Métodos de predicción y modulación de la glicación de una proteína
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
WO2022220603A1
(ko)
|
2021-04-16 |
2022-10-20 |
고려대학교 산학협력단 |
코로나-19 바이러스 표적 인간 항체
|
TW202305122A
(zh)
|
2021-04-19 |
2023-02-01 |
美商建南德克公司 |
經修飾之哺乳動物細胞
|
US11926661B2
(en)
|
2021-04-20 |
2024-03-12 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to artemin and methods of use thereof
|
IL307744A
(en)
|
2021-04-22 |
2023-12-01 |
Astellas Pharma Inc |
Anti-CLDN4/anti-CD137 bispecific antibody
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
MX2023012974A
(es)
|
2021-05-04 |
2023-11-15 |
Regeneron Pharmaceuticals Inc |
Agonistas multiespecificos de receptores del fgf21 y sus usos.
|
WO2022235759A1
(en)
|
2021-05-05 |
2022-11-10 |
Trianni, Inc. |
Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
CN117730099A
(zh)
|
2021-05-11 |
2024-03-19 |
瑞泽恩制药公司 |
抗tmprss6抗体及其用途
|
WO2022241446A1
(en)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
AU2022280767A1
(en)
|
2021-05-24 |
2024-01-18 |
Humabs Biomed Sa |
Engineered polypeptides
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
AR126054A1
(es)
|
2021-06-04 |
2023-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-ddr2 y usos de estos
|
WO2022258600A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
AU2022292462A1
(en)
|
2021-06-18 |
2023-12-07 |
Nammi Therapeutics, Inc. |
FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
|
EP4361176A1
(en)
|
2021-06-25 |
2024-05-01 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
CA3221833A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody
|
CA3226042A1
(en)
|
2021-07-05 |
2023-01-12 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
CA3224853A1
(en)
|
2021-07-14 |
2023-01-19 |
Gautham GAMPA |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
AU2022311906A1
(en)
|
2021-07-14 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
CA3219606A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
US20230146317A1
(en)
|
2021-07-26 |
2023-05-11 |
Sanofi Biotechnology |
Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
|
KR20240038928A
(ko)
|
2021-07-28 |
2024-03-26 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질-항바이러스 화합물 접합체
|
EP4380980A1
(en)
|
2021-08-03 |
2024-06-12 |
F. Hoffmann-La Roche AG |
Bispecific antibodies and methods of use
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
AU2022333073A1
(en)
|
2021-08-23 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
PE20240727A1
(es)
|
2021-08-27 |
2024-04-15 |
Janssen Biotech Inc |
Anticuerpos anti-psma y usos de estos
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
CA3230613A1
(en)
|
2021-09-01 |
2023-03-09 |
Daren J. AUSTIN |
Antibody therapies for sars-cov-2 infection in pediatric subjects
|
WO2023034871A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
High concentration antibody therapies for sars-cov-2 infection
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
WO2023039442A1
(en)
|
2021-09-08 |
2023-03-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibody combination therapies for sars-cov-2 infection
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
CA3232212A1
(en)
|
2021-10-01 |
2023-04-06 |
Ping XIANG |
Transgenic rodents for cell line identification and enrichment
|
TW202323810A
(zh)
|
2021-10-08 |
2023-06-16 |
日商中外製藥股份有限公司 |
預填充式注射器製劑的調製方法
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
US20230183362A1
(en)
|
2021-10-20 |
2023-06-15 |
Sanofi Biotechnology |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
WO2023070097A2
(en)
|
2021-10-22 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Factor xi a2 domain-binding antibodies and methods of use thereof
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
CA3235395A1
(en)
|
2021-11-10 |
2023-05-19 |
Peter Burrows |
Transgenic mammals and methods of use thereof
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
TW202337494A
(zh)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
用莫蘇妥珠單抗治療全身性紅斑狼瘡(sle)之方法及組成物
|
WO2023092052A1
(en)
|
2021-11-19 |
2023-05-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
WO2023089587A1
(en)
|
2021-11-22 |
2023-05-25 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
US20230250170A1
(en)
|
2021-12-06 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
WO2023130010A1
(en)
|
2021-12-30 |
2023-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for attenuating atopic march by administering an il-4/il-13 antagonist
|
WO2023137026A1
(en)
|
2022-01-12 |
2023-07-20 |
Regeneron Pharmaceuticals, Inc. |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
WO2023137443A1
(en)
|
2022-01-14 |
2023-07-20 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
TW202332767A
(zh)
|
2022-02-02 |
2023-08-16 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗TfR:GAA及抗CD63:GAA插入
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
WO2023154861A1
(en)
|
2022-02-11 |
2023-08-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
WO2023155902A1
(en)
|
2022-02-18 |
2023-08-24 |
Chongqing Mingdao Haoyue Biotechnology Co., Ltd. |
Intranasal formulations and anti-sars-cov-2-spike protein antibodies
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023201256A1
(en)
|
2022-04-12 |
2023-10-19 |
Vir Biotechnology, Inc. |
High dose antibody therapies for sars-cov-2 infection
|
JP2024517042A
(ja)
|
2022-04-13 |
2024-04-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法
|
US20240002491A1
(en)
|
2022-04-27 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202411247A
(zh)
|
2022-05-23 |
2024-03-16 |
瑞士商休曼生物醫藥股份公司 |
針對流感神經胺酸酶的廣泛中和抗體
|
WO2023230448A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Combination immunotherapy for influenza
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023245078A1
(en)
|
2022-06-15 |
2023-12-21 |
Humabs Biomed Sa |
Anti-parvovirus antibodies and uses thereof
|
WO2024006472A1
(en)
|
2022-06-30 |
2024-01-04 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
WO2024011251A1
(en)
|
2022-07-08 |
2024-01-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
|
WO2024015816A1
(en)
|
2022-07-12 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20240102045A1
(en)
|
2022-07-19 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026411A1
(en)
|
2022-07-27 |
2024-02-01 |
Humabs Biomed Sa |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
US20240052051A1
(en)
|
2022-07-29 |
2024-02-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
TW202405020A
(zh)
|
2022-07-29 |
2024-02-01 |
美商阿列克特有限責任公司 |
轉鐵蛋白受體抗原結合域及其用途
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024044770A1
(en)
|
2022-08-26 |
2024-02-29 |
Core Biotherapeutics, Inc. |
Oligonucleotides for the treatment of breast cancer
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
US20240130341A1
(en)
|
2022-09-29 |
2024-04-25 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024092133A1
(en)
|
2022-10-27 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
US20240141051A1
(en)
|
2022-11-01 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hand and foot dermatitis by administering an il-4r antagonist
|
US20240165227A1
(en)
|
2022-11-04 |
2024-05-23 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
US20240190996A1
(en)
|
2022-11-07 |
2024-06-13 |
Regeneron Pharmaceuticals, Inc. |
Factor xi catalytic domain-binding antibodies and methods of use thereof
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024107759A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
|
WO2024112818A1
(en)
|
2022-11-22 |
2024-05-30 |
Humabs Biomed Sa |
Engineered anti-sars-cov-2 antibodies and uses thereof
|
WO2024112935A1
(en)
|
2022-11-23 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for improving bone growth by administering an il-4r antagonist
|
WO2024118593A1
(en)
|
2022-11-28 |
2024-06-06 |
Allogene Therapeutics Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
WO2024118998A2
(en)
|
2022-12-01 |
2024-06-06 |
Vir Biotechnology, Inc. |
Engineered anti-sars-cov-2 antibodies and methods of using the same
|